Regulatory Insights

  1. Understanding When AI Models Need To Be Validated For Regulated Industries 4/15/2026

    Focus AI validation on decision impact rather than just algorithms. Aligning assurance with intended use and human oversight ensures safety while enabling faster, more compliant adoption.

  2. Countdown To Compliance: Navigating New UK Requirements 4/15/2026

    Senior experts from the HRA, the ISRCTN Registry (BMC), and Quotient Sciences discuss the implications of New UK regulations for clinical trial registration for sponsors and how to maintain compliance.

  3. Futureproofing Post-Approval Compliance 4/15/2026

    In the post-approval stage, a synergistic operating model brings PV and regulatory functions under one umbrella: a single governance structure with shared decision cycles, templates, and evidence.

  4. How Sponsors Can Ensure Their Sites Are Aligned With ICH E6 R3 4/14/2026

    Updated GCP expectations reshape sponsor–site collaboration. Clear guidance on systems, data governance, and monitoring reduces risk, strengthens oversight, and supports compliance with ICH E6(R3).

  5. How Australia's Leading CRO Is Driving Biotech's Acceleration From First-In-Human To Global Markets 4/8/2026

    The next era of clinical trials will be defined by global expansion across the Asia-Pacific region, rapid and cost-effective pathways to regulatory approval, and reliable, patient-centric leadership.

  6. UK Regulatory Reforms 4/7/2026

    Stay ahead of the evolving UK regulatory landscape and leverage upcoming reforms to accelerate patient access, drive innovation, and strengthen your position in the medicines development market.

  7. Real-World Evidence Revisited 4/6/2026

    Explore how the latest regulatory updates transform real-world data into a credible evidentiary pathway. Learn the new standards for data reliability and hybrid study design.

  8. General Wellness Isn't A Vibe Anymore: What The 2026 FDA Update Means 4/6/2026

    The FDA’s 2026 guidance has put an end to "wellness by disclaimer." Learn how new standards for wearables and apps impact study design, participant safety, and the evolving ethical role of the IRB.

  9. Clinical Decision Support Software: Clear Expectations For Research Oversight 4/6/2026

    The FDA’s 2026 CDS guidance signals a shift to settled policy. IRBs must now demand greater transparency regarding automation bias and clinician independence to accurately assess study risk.

  10. The FDA's Final BIMO "Processes And Practices" Guidance 4/6/2026

    Gain a clear roadmap for investigators, sponsors, and IRBs. This shift toward transparency replaces regulatory guesswork with predictable standards for every partner in the research ecosystem.